Ocular Therapeutics Receives Positive FDA Feedback on AXPAXLI

Ocular Therapeuticx (NASDAQ:OCUL) received positive feedback from the FDA during a Type C meeting, leading H.C. Wainwright to raise its price target for OCUL stock and maintain a Buy rating. The company plans to submit a New Drug Application in Q4 2026 based on trial results.

By Laiba Immad Thu, June 25, 2026 at 3:40 PM GMT+3 2 min read · Yahoo Finance · June 25, 2026, 12:40 UTC

Ocular Therapeutics Receives Positive FDA Feedback on AXPAXLI

Tickers: $OCUL

Topics: biopharmaceutical drug development fda feedback new drug application

Read the full article at Yahoo Finance

More World news

Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC
Suburban Propane Reports Fiscal 2026 Results with Increased Adjusted EBITDA and RNG Growth Motley Fool · November 12, 2026, 17:40 UTC
Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending Motley Fool · November 12, 2026, 17:40 UTC